UMass Chan AffiliationsDepartment of Surgery
MetadataShow full item record
AbstractSignificance: Rapid recruitment and activation of macrophages may accelerate wound healing. Such accelerated healing was observed in wounds and burns of experimental animals treated with alpha-gal nanoparticles. Recent Advances: alpha-Gal nanoparticles present multiple alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R). alpha-Gal nanoparticles applied to wounds bind anti-Gal (the most abundant antibody in humans) and generate chemotactic complement peptides, which rapidly recruit macrophages. Fc/Fc receptor interaction between anti-Gal coating the alpha-gal nanoparticles and recruited macrophages activates macrophages to produce cytokines that accelerate healing. alpha-Gal nanoparticles applied to burns and wounds in mice and pigs producing anti-Gal, decreased healing time by 40-60%. In mice, this accelerated healing avoided scar formation. alpha-Gal nanoparticle-treated wounds, in diabetic mice producing anti-Gal, healed within 12 days, whereas saline-treated wounds became chronic wounds. alpha-Gal nanoparticles are stable for years and may be applied dried, in suspension, aerosol, ointments, or within biodegradable materials. Critical Issues: alpha-Gal nanoparticle therapy can be evaluated only in mammalian models producing anti-Gal, including alpha1,3-galactosyltransferase knockout mice and pigs or Old World primates. Traditional experimental animal models synthesize alpha-gal epitopes and lack anti-Gal. Future Directions: Since anti-Gal is naturally produced in all humans, it is of interest to determine safety and efficacy of alpha-gal nanoparticles in accelerating wound and burn healing in healthy individuals and in patients with impaired wound healing such as diabetic patients and elderly individuals. In addition, efficacy of alpha-gal nanoparticle therapy should be studied in healing and regeneration of internal injuries such as surgical incisions, ischemic myocardium following myocardial infarction, and injured nerves.
SourceAdv Wound Care (New Rochelle). 2017 Mar 1;6(3):81-92. doi: 10.1089/wound.2016.0703. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/40323